By George Ongkojoyo 
In the complex landscape of oncology, regulatory T cells (Tregs) have long been characterized as the "brakes" of the immune system. In the majority of solid tumors, such as melanoma or lung cancer, a high concentration of these cells is typically a harbinger of poor clinical outcomes. By suppressing the body’s natural ability to detect and destroy malignant cells, Tregs effectively provide a shield for the tumor, allowing it to proliferate unchecked. However, for decades, colorectal cancer (CRC) has presented a baffling contradiction to this rule. In patients with CRC, a high density of Treg cells often correlates with improved survival rates, a phenomenon that has remained one of the most persistent mysteries in cancer immunology.
A landmark study published in the journal Immunity by researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has finally provided a definitive explanation for this anomaly. The research reveals that Tregs in the colorectal environment are not a monolithic population. Instead, they consist of two distinct subtypes with diametrically opposed functions: one that promotes tumor growth and another that unexpectedly restrains it. This discovery not only resolves a long-standing scientific debate but also paves the way for more precise immunotherapies targeting the most common and difficult-to-treat forms of colorectal cancer.
The Paradox of the Immune Brake in Colorectal Cancer
Colorectal cancer remains the second leading cause of cancer-related mortality worldwide when data for men and women are combined. While advancements in screening and surgical techniques have improved early detection, the prognosis for advanced cases—particularly those resistant to traditional immunotherapy—remains a significant challenge.
The primary hurdle lies in the biological classification of these tumors. Approximately 80% to 85% of colorectal cancers are categorized as microsatellite stable (MSS) with proficient mismatch repair (MMRp). Unlike the rarer microsatellite instability-high (MSI-H) tumors, which are "hot" or highly inflamed and responsive to checkpoint inhibitors like pembrolizumab, MSS tumors are considered "cold." They possess fewer mutations and are generally ignored by the immune system. Historically, checkpoint inhibitors, which work by releasing the "brakes" on the immune system, have failed to produce significant results in the vast majority of MSS colorectal cancer patients.
The MSK study, led by co-senior authors Alexander Rudensky, PhD, and Christina Leslie, PhD, suggests that the presence of "beneficial" Tregs in these tumors may be the reason for the survival correlation observed in historical data. Dr. Rudensky, a pioneer in the study of immune tolerance, has spent over 20 years investigating how Tregs prevent the immune system from attacking the body’s own tissues, helpful microbes, and dietary proteins.
Identifying the Dual Subtypes of Treg Cells
To investigate why Tregs behave differently in the gut, the research team employed a sophisticated mouse model designed to mimic the genetic mutations and immune environment of human colorectal tumors. Through high-resolution single-cell analysis and computational modeling, the team identified two primary subpopulations of Tregs within the tumor microenvironment.
The first group is defined by the production of interleukin-10 (IL-10), a signaling molecule known for its anti-inflammatory properties. These IL-10-positive Tregs were found to be beneficial. Their primary role in the tumor context is to suppress Th17 cells, a different class of immune cells that produce interleukin-17 (IL-17). In the specific environment of the colon, IL-17 acts as a potent growth factor for cancer cells. By keeping Th17 cells in check, IL-10-positive Tregs indirectly slow the progression of the tumor.
The second group, characterized as IL-10-negative Tregs, functions in a manner consistent with Tregs in other types of cancer. These cells suppress the "soldiers" of the immune system, specifically CD8+ T cells, which are responsible for killing cancer cells. These IL-10-negative Tregs are primarily located deep within the tumor mass and serve as the primary obstacle to an effective anti-tumor immune response.
Chronology of Discovery and Human Validation
The breakthrough did not occur in isolation but was the result of a multi-stage experimental process. After identifying the two subtypes in mouse models, the researchers moved to validate their findings using human tissue.
- Initial Mouse Modeling: The team observed that when all Treg cells were removed from the mouse models, the tumors actually grew faster. This confirmed that some Tregs were indeed providing a protective effect.
- Selective Depletion: Using genetic tools, the researchers selectively removed only the IL-10-producing Tregs. As predicted, tumor growth accelerated due to the unchecked rise of IL-17. Conversely, when they targeted the IL-10-negative Tregs, the tumors shrank, as the CD8+ T cells were finally able to attack the malignancy.
- Human Patient Correlation: The researchers analyzed tumor samples and clinical data from a cohort of over 100 colorectal cancer patients. The data mirrored the mouse results: patients with a higher ratio of IL-10-positive (beneficial) Tregs had significantly longer survival, while those with a preponderance of IL-10-negative (harmful) Tregs faced poorer outcomes.
Dr. Xiao Huang, a postdoctoral researcher and co-first author of the study, noted that this research underscores the complexity of the immune system. "It’s not just about the quantity of the immune cells," Huang stated. "It’s about the specific functional state of those cells within the unique environment of the organ."
CCR8: A New Target for Precision Immunotherapy
The identification of these two subtypes provides a clear target for the next generation of cancer treatments. The study found that the "harmful" IL-10-negative Tregs express high levels of a protein called CCR8. In contrast, the "beneficial" IL-10-positive Tregs do not express this protein to the same degree.
This distinction is critical for drug development. Current immunotherapies often act bluntly, affecting large swaths of the immune system and frequently causing "off-target" autoimmune side effects. By using antibodies that specifically target CCR8, clinicians may be able to selectively deplete the harmful Tregs within the tumor while leaving the protective Tregs intact.
This strategy was pioneered in earlier MSK research led by Dr. George Plitas and Dr. Rudensky, which found high CCR8 expression in breast cancer Tregs. The current study confirms that this target is equally relevant, if not more so, for colorectal cancer. Currently, several clinical trials are underway globally, including at MSK, to test CCR8-depleting antibodies. These trials are evaluating the drugs both as a standalone therapy and in combination with existing checkpoint inhibitors.
Broader Implications for Barrier Tissue Cancers
The research team extended their analysis to a massive dataset of T cells across 16 different cancer types. They discovered that the division between IL-10-positive and IL-10-negative Tregs is not unique to the colon. Similar patterns were observed in cancers arising from "barrier tissues"—areas of the body that are constantly exposed to the outside environment, such as the skin, the lining of the stomach, and the tissues of the mouth and throat.
In these tissues, the immune system has evolved to be highly regulated to prevent chronic inflammation from exposure to microbes and environmental toxins. Dr. Sneha Mitra, a co-first author who led the computational analysis, explained that these tissues share a common "immune logic." This suggests that a CCR8-targeted approach could be effective across a wide range of common malignancies beyond just colorectal cancer.
The Metastatic Shift: Why Context Matters
One of the most striking findings of the study was the change in immune behavior when the cancer spreads. When the researchers examined colorectal cancer that had metastasized to the liver, the protective IL-10-positive Tregs were largely absent. In the liver environment, the harmful IL-10-negative Tregs dominated the landscape.
In this metastatic context, removing all Treg cells caused the tumors to shrink—aligning with how Tregs behave in most other solid tumors. This highlights a crucial lesson for precision medicine: the effectiveness of an immunotherapy may depend entirely on the anatomical site of the tumor and the stage of the disease. A treatment that works for a primary tumor in the colon might need to be adjusted if the cancer moves to the liver.
Conclusion and Future Outlook
The findings from the Rudensky and Leslie labs represent a paradigm shift in how oncologists view the role of the immune system in colorectal cancer. By resolving the "Treg paradox," the study provides a biological roadmap for treating the 85% of CRC patients who have historically been left behind by the first wave of immunotherapy.
The shift toward selective depletion—targeting only the cells that fuel the disease while sparing those that restrain it—marks a move toward more "surgical" precision in immunotherapy. As clinical trials for CCR8-targeted agents progress, the oncology community is hopeful that these findings will translate into higher survival rates and fewer side effects for patients facing one of the world’s most prevalent and deadly forms of cancer.
The study was supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Ludwig Center for Cancer Immunotherapy at MSK, among other prestigious institutions. With patents already filed for CCR8-based therapies, the transition from the laboratory to the bedside is already well underway.